Hagit Binder - 26 Mar 2026 Form 4 Insider Report for NeuroSense Therapeutics Ltd. (NRSN)

Reporting relationship: General Manager
Issuer ticker: NRSN
Reported as of: 26 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Mar 2026, 08:49:28 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Hagit Binder

Key filing fact

Hagit Binder filed Form 4 for NeuroSense Therapeutics Ltd. (NRSN) on 30 Mar 2026.

Key facts

This page summarizes Hagit Binder's Form 4 filing for NeuroSense Therapeutics Ltd. (NRSN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Mar 2026, 08:49.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002118272 Primary reporting owner

Binder Hagit

Relationship: General Manager
Address: C/O NEUROSENSE THERAPEUTICS LTD., 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, ISRAEL
Signature: /s/ Hagit Binder
Signature date: 30 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRSN transaction

Ordinary Shares

Award

Transaction value
Shares: +200,000
Change %: +62%
Price: $0.000000^*
Shares after: 521,806
Date: 26 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.

Footnote F2

The restricted shares vest in equal quarterly installments over a two-year period, commencing on the grant date of March 26, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.